Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to four newly-hired, non-executive employees on March 24, 2026 and to its newly-hired President and Chief Executive Officer, Jennifer Jarrett, on March 30, 2026. The inducement grants were approved by Damora’s Board of Directors or its independent Compensation Committee and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants made on March 24, 2026 to the non-executive employees consist of non-qualified stock options to purchase an aggregate of 74,000 shares of Damora’s common stock with a 10-year term and an exercise price of $23.05 per share. In connection with Ms. Jarrett’s appointment as President and Chief Executive Officer, on March 30, 2026, she received a grant of 500,000 restricted stock units ("RSUs") and non-qualified stock options to purchase 1,500,000 shares of Damora’s common stock at an exercise price of $25.50 per share. All of the options vest as to 25% on the first anniversary of the applicable grant date and in equal monthly installments for the following 36 months, and the RSUs vest annually over four years. The inducement grants are subject to the terms and conditions of the 2022 Damora Therapeutics, Inc. Inducement Plan, and the terms and conditions of a stock option or RSU award agreement.

About Damora Therapeutics

Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. For more information, visit or follow us on LinkedIn.

Media Contact:

Lia Dangelico

Deerfield Group

Investor Contact:

Brian Ritchie

LifeSci Advisors